title: Successful treatment of idiopathic orbital inflammation with mycophenolate mofetil.
abstract: OBJECTIVE
  To report our experience with the use of mycophenolate mofetil for treatment of idiopathic orbital inflammation (IOI).
  
  
  METHODS
  Noncomparative interventional case series.
  
  
  METHODS
  We reviewed the records of five patients with IOI who were treated with mycophenolate mofetil. The indications for use included recurrent inflammation after other therapies (four patients) and to avoid corticosteroid-induced blood sugar elevation in poorly controlled diabetes mellitus (one patient). Treated patients were followed for a median of 8.5 months (range, 4-30 months) after mycophenolate mofetil therapy was begun. Main outcome measures were response to treatment, treatment-related side effects, drug dosage, previous and final treatment regimens, and discontinuation of systemic corticosteroids.
  
  
  RESULTS
  Mycophenolate mofetil therapy was discontinued in one patient because of nausea. Each of the remaining four patients experienced complete resolution of orbital inflammation. Of these, only one patient remains on prednisone, but at a significantly reduced dose (1 mg/d).
  
  
  CONCLUSIONS
  Mycophenolate mofetil therapy resulted in the resolution of inflammation in patients with refractory or corticosteroid-dependent IOI and was used successfully for a first episode of IOI in a patient for whom corticosteroids were contraindicated.
authors.affiliation: Department of Oculoplastic, Orbit, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA.
authors.forename: Mark P
authors.initials: MP
authors.lastname: Hatton
authors.forename: Peter A D
authors.initials: PA
authors.lastname: Rubin
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016727:Orbital Pseudotumor / Q000188:drug therapy*; D011355:Prodrugs / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011355:Prodrugs; D009173:Mycophenolic Acid